Annexon (ANNX) vs Attovia Therapeutics (ATTO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Annexon is the larger company by market cap ($758.3 million vs $744.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANNX | ATTO |
|---|---|---|
| Share price | $4.00 | $16.31 |
| Market cap | $758.32M | $744.57M |
| 1-day change | -0.25% | -0.67% |
| YTD return | -20.12% | — |
| 1-year return | +30.62% | — |
| 5-year return | -81.77% | — |
| EPS (TTM) | $-1.13 | $-2.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.18 | $28.00 |
| 52-week low | $2.54 | $15.48 |
| Distance from 52-week high | -44.29% | -41.75% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +285.75% | +158.74% |
| Average volume | 3.11M | 458.24K |
| Shares outstanding | 189.58M | 45.65M |
| Employees | 92 | 44 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Annexon
ANNX stock →Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
About Attovia Therapeutics
ATTO stock →Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 44 employees
ANNX vs ATTO FAQ
Which is bigger, Annexon or Attovia Therapeutics?
Annexon (ANNX) is larger, with a market capitalization of $758.32M compared with $744.57M for Attovia Therapeutics (ATTO).
Are Annexon and Attovia Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Annexon and Biotechnology: Biological Products (No Diagnostic Substances) for Attovia Therapeutics.